文献速递白血病淋巴瘤

Fc工程化CD19抗体在患者来源的MLL重排急性淋巴细胞白血病异种移植模型中清除微小残留病

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
PubMed 文献 · Blood · 2017-07-11

研究在NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ(NSG)小鼠中建立儿童MLL重排B细胞前体急性淋巴细胞白血病(BCP-ALL)患者来源异种移植(PDX)模型,评估携带S239D/I332E突变的Fc工程化CD19抗体(CD19-DE)的疗效与机制。CD19-DE在微小残留病(MRD)模型中延长生存,多数存活小鼠治疗后PCR-MRD阴性;在显性白血病中起始治疗仍延长生存但效果不如MRD设置;与地塞米松、长春新碱、PEG-天冬酰胺酶化疗减瘤联合显著改善生存率。在13例MLL重排BCP-ALL样本的随机2期样PDX试验中CD19-DE同样有效;脂质体氯膦酸盐耗竭巨噬细胞可逆转CD19-DE的获益,体外CD19-DE增强人巨噬细胞对患者来源ALL原始细胞的吞噬作用。

要点

  • CD19-DE在MRD模型延长NSG小鼠生存,多数存活小鼠治疗后PCR-MRD阴性。
  • 显性白血病中起始CD19-DE仍延长生存,但效果不如MRD设置。
  • CD19-DE联合地塞米松、长春新碱、PEG-天冬酰胺酶化疗减瘤显著改善异种移植小鼠生存率。

核心结论

  • Fc工程化CD19抗体可能为化疗后预后不良的MLL重排BCP-ALL婴幼儿和儿童提供有前景的治疗选择。

研究设计与样本

  • 在NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ(NSG)小鼠中建立儿童MLL重排ALL患者来源异种移植(PDX)模型,测试携带S239D/I332E突变的Fc工程化CD19抗体(CD19-DE)。
  • 开展使用13例MLL重排BCP-ALL样本的随机2期样PDX试验评估CD19-DE。

主要发现

  • CD19-DE在MRD模型中有效延长NSG小鼠生存,多数存活小鼠治疗后PCR-MRD阴性。
  • 在显性白血病中起始CD19-DE治疗仍较未治疗对照动物有效延长异种移植小鼠生存,但效果不如MRD设置显著。
  • CD19-DE联合地塞米松、长春新碱、PEG-天冬酰胺酶化疗减瘤显著改善异种移植小鼠生存率。
  • 脂质体氯膦酸盐耗竭巨噬细胞逆转CD19-DE的获益,提示巨噬细胞作为效应细胞的重要作用。
  • 体外CD19-DE增强人巨噬细胞对患者来源ALL原始细胞的吞噬作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody therapy constitutes a major advance in the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). To evaluate the efficacy and the mechanisms of action of CD19 monoclonal antibody therapy in pediatric BCP-ALL, we tested an Fc-engineered CD19 antibody carrying the S239D/I332E mutation for improved effector cell recruitment (CD19-DE). Patient-derived xenografts (PDX) of pediatric mixed-lineage leukemia gene (MLL)-rearranged ALL were established in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Antibody CD19-DE was efficient in prolonging the survival of NSG mice in a minimal residual disease (MRD) model. The majority of surviving mice remained polymerase chain reaction (PCR)-MRD negative after treatment. When antibody therapy was initiated in overt leukemia, antibody CD19-DE was still efficient in prolonging survival of xenografted mice in comparison with nontreated control animals, but the effects were less pronounced than in the MRD setting. Importantly, the combination of antibody CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparaginase) resulted in significantly improved survival rates in xenografted mice. Antibody CD19-DE treatment was also efficient in a randomized phase 2-like PDX trial using 13 MLL-rearranged BCP-ALL samples. Macrophage depletion by liposomal clodronate resulted in a reversal of the beneficial effects of CD19-DE, suggesting an important role for macrophages as effector cells. In support of this finding, CD19-DE was found to enhance phagocytosis of patient-derived ALL blasts by human macrophages in vitro. Thus, Fc-engineered CD19 antibodies may represent a promising treatment option for infants and children with MLL-rearranged BCP-ALL who have a poor outcome when treated with chemotherapy only.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schewe DM, Alsadeq A, Sattler C, et al. An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts. Blood. 2017. PMID: 28698205. doi:10.1182/blood-2017-01-764316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。